Eribulin mesylate in pretreated breast cancer patients: A multicenter retrospective observational study

Teresa Gamucci, Andrea Michelotti, Laura Pizzuti, Lucia Mentuccia, Elisabetta Landucci, Isabella Sperduti, Luigi Di Lauro, Alessandra Fabi, Giuseppe Tonini, Valentina Sini, Nello Salesi, Ilaria Ferrarini, Angela Vaccaro, Ida Pavese, Enzo Veltri, Luca Moscetti, Paolo Marchetti, Patrizia Vici

Research output: Contribution to journalArticlepeer-review


Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease. Objectives: This multicenter observational retrospective study was performed in order to evaluate activity and tolerability of eribulin in real-world patient population. Methods: 133 advanced breast cancer patients pretreated with = 2 chemotherapy lines for metastatic disease were retrospectively enrolled in the observational trial in 11 italian cancer centres. Results: A median of 5 cycles of eribulin (range, 1-15) were administered. Twenty-eight partial responses were observed, for an overall response rate of 21.1% (95%CI,14.1-28.0). A stable disease was recorded in 57 patients (42.8%), and a clinical benefit (response or stable disease lasting = six months) was observed in 51 patients (38.3%, 95%CI, 30.1-46.6). The subgroup analysis showed that a significant improvement in term of partial response and clinical benefit was achieved when eribulin was administered in HER-2 negative tumors (p=0.01 and p=0.004, respectively) and when it is given as third-line (p=0.09 and p=0.02, respectively). Toxicity was manageable fatigue is the most common side effect observed, usually of low-grade, and clearly cumulative-dose related. Conclusions: In this retrospective, observational analysis eribulin confirmed its efficacy and manageable tolerability even in real-world population and in heavily pretreated patients.

Original languageEnglish
Pages (from-to)320-327
Number of pages8
JournalJournal of Cancer
Issue number5
Publication statusPublished - 2014


  • Advanced breast cancer
  • Chemotherapy
  • Eribulin mesylate
  • Heavily pretreated patients
  • Real-world population

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Eribulin mesylate in pretreated breast cancer patients: A multicenter retrospective observational study'. Together they form a unique fingerprint.

Cite this